Objectives The aim of this multicenter study was to gather epidemiological data on candidemia in the Belgian population. Another goal was to determine the time in real life setting for reporting to the treating physicians of the species involved and its antifungal susceptibility. Methods Prospective study in 29 Belgian hospitals. From March 1st, 2013 till February 28, 2014 the first Candida isolate from each episode of candidemia was included. Identification and susceptibility testing were performed according to local procedures and isolates were sent to the National Reference Lab with a completed case report form. Species identification was checked by MALDI-TOF mass spectrometry (MS) and ITS sequencing in case no reliable identification was obtained by MS. Antifungal susceptibility testing was performed according to EUCAST guidelines. The total number of patient admissions and hospitalization days during the study period was retrieved from each hospital. Results 341 isolates were retrieved from 325 patients (53.2% male, median age 66 years, range 1-94 years) admitted to the ICU (34.4%), medical wards (30.8%), surgical wards (15.2%), onco-haematology (10.6%), pediatrics (3.0%), neonatology (1.7%) and other wards (4.3%). The mean incidence rate of candidemia was 0.42 per 1,000 admissions (range 0.07 to 1.44) and 0.60 per 10,000 patient days (range from 0.11 to 2.03). Candida albicans was the main cause of candidemia (51.9%), followed by Candida glabrata (26.7%), Candida parapsilosis (9.9%), Candida tropicalis (4.4%), Candida guilliermondii (2.6%), Candida dubliniensis (1.5%), Candida lusitaniae (1.2%), Candida krusei (1.2%) and Candida metapsilosis (0.6%). Overall resistance to fluconazole was 6.7% and to anidulafungin 0.6% (2 C. glabrata isolates were echinocandin resistant). Resistance to amphotericin B was detected in 1 C. tropicalis isolate, all C. albicans, C. glabrata and C. parapsilosis isolates remained susceptible to this drug. Resistance to fluconazole ranged from 3.5% in C. albicans, 8.6% in C. ...